Hizentra Articles
CSL Behring gets European OK for Hizentra
26 April 2011
Novartis gains positive CHMP opinion for Rasilamlo, as do CSL Behring for Hizentra and Provepharm for Proveblue
21 February 2011
Showing 1-2 of 2 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
